期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
苏格兰的药物团体否决Foscan和Botox
1
作者 范丽珠 《国外药讯》 2004年第10期45-45,共1页
关键词 苏格兰 光动力学药物 FOSCAN BOTOX A型肉毒杆菌毒素 头颈部癌症
下载PDF
Determination of Clarithromycin in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Validation and Application in Clinical Pharmacokinetic Study 被引量:7
2
作者 ZHANGXiang-rong CHENXiao-yan LIXiao-yan ZHONGDa-fang 《Journal of Chinese Pharmaceutical Sciences》 CAS 2004年第3期166-170,共5页
Aim To develop a liquid chromatographic-tandem mass spectrometric (LC-MS-MS)method to determine clarithromycin in human plasma. Methods The analyte and internal standardroxithromycin were extracted from plasma samples... Aim To develop a liquid chromatographic-tandem mass spectrometric (LC-MS-MS)method to determine clarithromycin in human plasma. Methods The analyte and internal standardroxithromycin were extracted from plasma samples by n-nexane-dichloromethane-isopropanol(300:150:15, V/V/V) and chromalographed on a C_(18) column. The mobile phase consisted ofmethanol-water-formic acid (80 = 20:1, V/V/V) . Detection was performed on a triple quadrupoletandem mass spectrometer via electrospray ionization source (ESI) in the positive mode. Results Themethod had a lower limit of quantification of 10.0 ng·mL^(-1) when 0.2 mL plasma was used. Thelinear calibration curves were obtained in the concentration range of 10.0 - 5000 ng·mL^(-1) . Theintra- and inter-run precisions were lower than 3.3% in terms of relative standard deviation (RSD),and the accuracy ranged +- 0.7% in terms of relative error (RE). T_(max), C_(max), T_(1/2) andAUC_(0-24h), values were found to be (3.1 +- 2.7)h, (8 750+-4734) ng·mL^(-1), (5.3+-2.2) h, and(5932+-2449)ng·mL^(-1), respectively, after a single oral dose of 250 mg clarithromycin tablet to18 volunteers. Conclusion This validated method was successful in the evaluation of phaimacokineticprofiles of clarithromycin tablets administered to 18 healthy male volunteers. 展开更多
关键词 CLARITHROMYCIN LC-MS-MS pharmaookmeties
下载PDF
Pharmacokinetics and Biodegradation Performance of a Hydroxypropyl Chitosan Derivative 被引量:5
3
作者 SHAO Kai HAN Baoqin +3 位作者 DONG Wen SONG Fulai LIU Weizhi LIU Wanshun 《Journal of Ocean University of China》 SCIE CAS 2015年第5期888-896,共9页
Hydroxypropyl chitosan(HP-chitosan) has been shown to have promising applications in a wide range of areas due to its biocompatibility, biodegradability and various biological activities, especially in the biomedical ... Hydroxypropyl chitosan(HP-chitosan) has been shown to have promising applications in a wide range of areas due to its biocompatibility, biodegradability and various biological activities, especially in the biomedical and pharmaceutical fields. However, it is not yet known about its pharmacokinetics and biodegradation performance, which are crucial for its clinical applications. In order to lay a foundation for its further applications and exploitations, here we carried out fluorescence intensity and GPC analyses to determine the pharmacokinetics mode of fluorescein isothiocyanate-labeled HP-chitosan(FITC-HP-chitosan) and its biodegradability. The results showed that after intraperitoneal administration at a dose of 10 mg per rat, FITC-HP-chitosan could be absorbed rapidly and distributed to liver, kidney and spleen through blood. It was indicated that FITC-HP-chitosan could be utilized effectively, and 88.47% of the FITC-HP-chitosan could be excreted by urine within 11 days with a molecular weight less than 10 k Da. Moreover, our data indicated that there was an obvious degradation process occurred in liver(< 10 k Da at 24 h). In summary, HP-chitosan has excellent bioavailability and biodegradability, suggesting the potential applications of hydroxypropyl-modified chitosan as materials in drug delivery, tissue engineering and biomedical area. 展开更多
关键词 hydroxypropyl chitosan fluorescein isothiocyanate PHARMACOKINETICS biodegradation performance biomedicalmaterial
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部